Clinical trial
Intensive Insulin Glulisine Therapy in Patients With Type 2 Diabetes…
NCT01203111 · Sanofi, Industry · Completed
Key facts
| NCT number | NCT01203111 |
|---|---|
| Title | Intensive Insulin Glulisine Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Basal Insulin and Oral Glucose-lowering Drugs |
| Official title | Efficacy and Safety of Intensive Insulin Therapy With Insulin Glulisine in Patients With Type 2 Diabetes Inadequately Controlled With Basal Insulin and Oral Glucose-lowering Drugs |
| Acronym | CHANGING |
| Lead sponsor | Sanofi, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Diabetes Mellitus, Type 2 |
| Intervention type | Drug |
| Interventions | INSULIN GLARGINE, INSULIN GLULISINE |
| Enrollment | 207 |
| Start date | Dec 1, 2010 |
| Primary completion | Jul 1, 2012 |
| Completion | Jul 1, 2012 |
| First posted | Sep 16, 2010 |
| Last update posted | Aug 30, 2012 |
| Countries | Algeria, Brazil, Israel, Lebanon, Mexico, Morocco, Peru, Saudi Arabia, United Arab Emirates, Venezuela |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: